{"title":"利用集合机器学习模型从组织病理学图像预测乳腺癌复发","authors":"Ghanashyam Sahoo, Ajit Kumar Nayak, Pradyumna Kumar Tripathy, Amrutanshu Panigrahi, Abhilash Pati, Bibhuprasad Sahu, Chandrakanta Mahanty, Saurav Mallik","doi":"10.3390/curroncol31110486","DOIUrl":null,"url":null,"abstract":"<p><p>Relapse and metastasis occur in 30-40% of breast cancer patients, even after targeted treatments like trastuzumab for HER2-positive breast cancer. Accurate individual prognosis is essential for determining appropriate adjuvant treatment and early intervention. This study aims to enhance relapse and metastasis prediction using an innovative framework with machine learning (ML) and ensemble learning (EL) techniques. The developed framework is analyzed using The Cancer Genome Atlas (TCGA) data, which has 123 HER2-positive breast cancer patients. Our two-stage experimental approach first applied six basic ML models (support vector machine, logistic regression, decision tree, random forest, adaptive boosting, and extreme gradient boosting) and then ensembled these models using weighted averaging, soft voting, and hard voting techniques. The weighted averaging ensemble approach achieved enhanced performances of 88.46% accuracy, 89.74% precision, 94.59% sensitivity, 73.33% specificity, 92.11% F-Value, 71.07% Mathew's correlation coefficient, and an AUC of 0.903. This framework enables the accurate prediction of relapse and metastasis in HER2-positive breast cancer patients using H&E images and clinical data, thereby assisting in better treatment decision-making.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 11","pages":"6577-6597"},"PeriodicalIF":2.8000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11592466/pdf/","citationCount":"0","resultStr":"{\"title\":\"Predicting Breast Cancer Relapse from Histopathological Images with Ensemble Machine Learning Models.\",\"authors\":\"Ghanashyam Sahoo, Ajit Kumar Nayak, Pradyumna Kumar Tripathy, Amrutanshu Panigrahi, Abhilash Pati, Bibhuprasad Sahu, Chandrakanta Mahanty, Saurav Mallik\",\"doi\":\"10.3390/curroncol31110486\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Relapse and metastasis occur in 30-40% of breast cancer patients, even after targeted treatments like trastuzumab for HER2-positive breast cancer. Accurate individual prognosis is essential for determining appropriate adjuvant treatment and early intervention. This study aims to enhance relapse and metastasis prediction using an innovative framework with machine learning (ML) and ensemble learning (EL) techniques. The developed framework is analyzed using The Cancer Genome Atlas (TCGA) data, which has 123 HER2-positive breast cancer patients. Our two-stage experimental approach first applied six basic ML models (support vector machine, logistic regression, decision tree, random forest, adaptive boosting, and extreme gradient boosting) and then ensembled these models using weighted averaging, soft voting, and hard voting techniques. The weighted averaging ensemble approach achieved enhanced performances of 88.46% accuracy, 89.74% precision, 94.59% sensitivity, 73.33% specificity, 92.11% F-Value, 71.07% Mathew's correlation coefficient, and an AUC of 0.903. This framework enables the accurate prediction of relapse and metastasis in HER2-positive breast cancer patients using H&E images and clinical data, thereby assisting in better treatment decision-making.</p>\",\"PeriodicalId\":11012,\"journal\":{\"name\":\"Current oncology\",\"volume\":\"31 11\",\"pages\":\"6577-6597\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-10-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11592466/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/curroncol31110486\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/curroncol31110486","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Predicting Breast Cancer Relapse from Histopathological Images with Ensemble Machine Learning Models.
Relapse and metastasis occur in 30-40% of breast cancer patients, even after targeted treatments like trastuzumab for HER2-positive breast cancer. Accurate individual prognosis is essential for determining appropriate adjuvant treatment and early intervention. This study aims to enhance relapse and metastasis prediction using an innovative framework with machine learning (ML) and ensemble learning (EL) techniques. The developed framework is analyzed using The Cancer Genome Atlas (TCGA) data, which has 123 HER2-positive breast cancer patients. Our two-stage experimental approach first applied six basic ML models (support vector machine, logistic regression, decision tree, random forest, adaptive boosting, and extreme gradient boosting) and then ensembled these models using weighted averaging, soft voting, and hard voting techniques. The weighted averaging ensemble approach achieved enhanced performances of 88.46% accuracy, 89.74% precision, 94.59% sensitivity, 73.33% specificity, 92.11% F-Value, 71.07% Mathew's correlation coefficient, and an AUC of 0.903. This framework enables the accurate prediction of relapse and metastasis in HER2-positive breast cancer patients using H&E images and clinical data, thereby assisting in better treatment decision-making.
期刊介绍:
Current Oncology is a peer-reviewed, Canadian-based and internationally respected journal. Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy in Canada to report upon and to review progress in the management of this disease.
We encourage submissions from all fields of cancer medicine, including radiation oncology, surgical oncology, medical oncology, pediatric oncology, pathology, and cancer rehabilitation and survivorship. Articles published in the journal typically contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine.